Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference

GAITHERSBURG, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10, 2026, at 9:30 a.m. ET.

GlobeNewsWire • Sep 3, 2026

Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?

ALT's stronger cash position supports pemvidutide's MASH, AUD and ALD programs, but long timelines, funding needs and competition remain risks.

Zacks Investment Research • Aug 19, 2026

Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus

ALT has moved pemvidutide into Phase III MASH testing, with supportive mid-stage data, regulatory backing and a 2029 readout ahead.

Zacks Investment Research • Aug 19, 2026

ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus

Altimmune posts a narrower Q2 loss. Its $519M in cash supports operations into 2029, while pemvidutide advances across liver and AUD studies.

Zacks Investment Research • Aug 13, 2026

Altimmune Q2 Earnings Call Highlights

Altimmune NASDAQ: ALT said it has initiated patient enrollment in its global Phase III PERFORMA trial of pemvidutide for metabolic dysfunction-associated steatohepatitis, or MASH, while advancing plans for later-stage development in alcohol use disorder, or AUD.

MarketBeat • Aug 12, 2026

Altimmune, Inc. (ALT) Q2 2026 Earnings Call Transcript

Altimmune, Inc. (ALT) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 12, 2026

Altimmune Announces Second Quarter 2026 Financial Results and Business Update

Initiated global PERFORMA Phase 3 trial in MASH Reported positive topline data from RECLAIM Phase 2 trial in AUD Completed patient enrollment in RESTORE Phase 2 trial in ALD $519 million in cash, cash equivalents and investments as of June 30, 2026 Webcast to be held today at 8:30 a.m. ET GAITHERSBURG, Md.

GlobeNewsWire • Aug 12, 2026

Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

GAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its second quarter 2026 financial results on Wednesday, August 12, 2026.

GlobeNewsWire • Aug 5, 2026

Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH

Global registrational study designed to evaluate pemvidutide on fibrosis improvement, MASH resolution, and clinical outcomes

GlobeNewsWire • Aug 3, 2026

Altimmune's drug meets main goal of mid-stage study for alcohol use disorder

Altimmune said on Tuesday its ​experimental drug met ‌the main goal of a mid-stage trial to help ​people with alcohol ​use disorder.

Reuters • Jul 28, 2026